Trials / Unknown
UnknownNCT02727309
A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
A Pilot Study of Second-line Treatment With Apatinib After Trans Arterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma Patients
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy and safety of TACE combined with apatinib in treating advanced hepatocellular carcinoma. The primary endpoint is progression-free survival (PFS), 3-month PFS, 6-month PFS and 1-year PFS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity. |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-12-01
- Completion
- 2019-03-01
- First posted
- 2016-04-04
- Last updated
- 2016-04-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02727309. Inclusion in this directory is not an endorsement.